Demeclocycline

For infections caused by drug-resistant bacteria such as *Staphylococcus aureus* and *Streptococcus pneumoniae*, there is a long-standing clinical demand for drugs with broad-spectrum antibacterial activity and low propensity to induce cross-resistance. As a classic tetracycline antibiotic, demeclocycline exerts bacteriostatic activity by reversibly binding to the 30S subunit of bacterial ribosomes, blocking the interaction between aminoacyl-tRNA and the ribosomal binding site, and inhibiting bacterial protein synthesis. It is clinically mainly used for the treatment of infectious diseases such as rickettsiosis, mycoplasma pneumonia, brucellosis and cholera, and can also be used for hyponatremia caused by syndrome of inappropriate antidiuretic hormone secretion. It is a commonly used alternative drug in the departments of infectious diseases and endocrinology.

The current tetracycline API market maintains a steady growth trend. In 2023, the global market size was approximately USD 1.27 billion, with a compound annual growth rate of around 3.8%. As a subdivided variety launched relatively early among tetracyclines, demeclocycline has a relatively concentrated market competition pattern. At present, the global production capacity is mainly concentrated in China and India. Domestic enterprises, relying on cost advantages and the expansion of compliant production capacity, account for more than 60% of the global supply. Due to its early launch, demeclocycline is no longer subject to compound patent restrictions, its generic drug preparation process is mature, and it has not been included in the national centralized drug procurement scope, so the overall market supply price remains stable.

The original research enterprise of demeclocycline is Pfizer, with the original brand name Declomycin. The core compound patent expired globally in 1972. The main dosage form approved for the original product is tablet, with specifications of 150 mg and 300 mg, which has been included in the FDA Reference Listed Drug Catalog. As of July 2025, there is no publicly announced demeclocycline API registration number in the database of the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China, and no preparation of this variety has been approved for marketing in China. (Data as of July 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of demeclocycline impurity reference standards. The products meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA. Most products are in regular stock. Orders placed before 16:00 can be shipped on the same day, which can efficiently meet the reference standard requirements in different stages such as API R&D, quality research, and registration submission.